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Abstract: Antimicrobial peptides (AMPs) are potent antibiotics of the innate immune system that 13 
have been extensively investigated as a potential solution to the global problem of infectious 14 
diseases caused by pathogenic microbes. A group of AMPs that are increasingly being reported are 15 
those that utilise pH dependent antimicrobial mechanisms and here, we review research into this 16 
area. This review shows that these antimicrobial molecules are produced by a diverse spectrum of 17 
creatures, including vertebrates and invertebrates, and are primarily cationic although a number of 18 
anionic examples are known. Some of these molecules exhibit high pH optima for their 19 
antimicrobial activity but in most cases, these AMPs show activity against microbes that present 20 
low pH optima, which reflects the acidic pH generally found at their sites of action, particularly the 21 
skin. The modes of action used by these molecules are based on a number of major structure / 22 
function relationships, which include metal ion binding, changes to net charge and conformational 23 
plasticity, and primarily involve the protonation of histidine, aspartic acid and glutamic acid 24 
residues at low pH. The pH dependent activity of pore forming antimicrobial proteins involves 25 
mechanisms that generally differ fundamentally to those used by pH dependent AMPs, which can 26 
be described by the carpet, toroidal pore and barrel-stave pore models of membrane interaction. A 27 
number of pH dependent AMPs and antimicrobial proteins have been developed for medical 28 
purposes and have successfully completed clinical trials, including kappacins, LL-37, histatins and 29 
lactoferrin, along with a number of their derivatives. Major examples of the therapeutic application 30 
of these antimicrobial molecules include wound healing as well as the treatment of multiple cancers 31 
and infections due to viruses, bacteria and fungi. In general, these applications involve topical 32 
administration, such as the use of mouth washes, cream formulations and hydrogel delivery 33 
systems. Nonetheless, many pH dependent AMPs and antimicrobial proteins have yet to be fully 34 
characterized and these molecules, as a whole, represent an untapped source of novel biologically 35 
active agents that could aid fulfillment of the urgent need for alternatives to conventional antibiotics, 36 
helping to avert a return to the pre-antibiotic era. 37 
 38 
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1. Introduction 43 
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A multiplicity of synergistic factors, including diminished pharmaceutical investment, clinical 44 
over-prescription and misuse by the food industry has led to the increasing occurrence of microbial 45 
pathogens with multiple drug resistance (MDR) and rendered infectious diseases the leading cause 46 
of global mortality [1]. This bleak situation led the World Health Organization (WHO) to recently 47 
predict that the uncurbed rise of MDR pathogens could see conditions in the 21st Century return to 48 
those of the pre-antibiotic era when no antimicrobials were available for the treatment of many 49 
common diseases [2]. In response, a major analysis by the WHO and a report from the OȂNeill review, 50 
sponsored by the UK Government, have concluded that the problem of antimicrobial drug resistance 51 
can only be fully addressed by a coordinated global approach that operates through a number of 52 
major interventions (Table 1) [3]. In particular, intervention six (Table 1) proposed the urgent 53 
development of novel products and strategies that could provide alternatives to conventional 54 
antibiotics, which has generated intensive research into antimicrobial design [4]. Examples of this 55 
research range from revisiting old anti-infective strategies, such as phage therapy, which was popular 56 
in Eastern European countries in the early 20th Century [5], to recently reported antimicrobial 57 
strategies, such as the development of compounds whose antibiotic activity can be regulated by light 58 
and sound [4,6-8]. One particularly promising approach proposed by OȂNeill [3] was the therapeutic 59 
development of antimicrobial peptides (AMPs), which are potent antibiotics of the innate immune 60 
system [9,10]. The activity of these peptides against microbes involves relatively non-specific modes 61 
of action at multiple sites with the result that microbial resistance to AMPs has a low incidence and 62 
is generally due to inherent rather than adaptive mechanisms [11]. Based on these observations, the 63 
generally held view is that microbial resistance to AMPs is unlikely to approach those of conventional 64 
antibiotics, endowing these peptides with a major medical advantage [10], and currently, a number 65 
of AMPs are in clinical trials (Table 2).    66 
 67 
Table 1: Major areas of intervention to combat antimicrobial drug resistance  68 
1. A global public awareness campaign. 
2. Improve sanitation and hygiene to prevent the spread of infection. 
3. Reduce the unnecessary use of antimicrobials in agriculture and their dissemination 
in the environment. 
4. Improve the global surveillance of drug resistance and antimicrobial consumption in 
humans and animals. 
5. Promote new rapid diagnostics to reduce use of unnecessary antimicrobials. 
6. Promote the development and use of vaccines and alternatives 
7. Improve the number, pay and recognition of people working in infectious disease. 
 
8. A global innovation fund for early stage and non-commercial research and 
development.  
 
9. Better incentives to promote investment for new drugs. 
Table 1 was derived from [3]  69 
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Table 2: Major examples of AMPs in clinical trials or in development  70 
Antimicrobial peptides Indication Phase Company  
Pexiganan (MSI-78), an 
analogue of magainin.  
Topical cream for the treatment of 
diabetic foot infections and ulcers. 
3 Dipexium Pharma 
/MacroChem / 
Genaera 
Iseganan (IB-367), a 
derivative of protegrin 
1. 
Mouthwash for the treatment of 
chemotherapy induced oral 
mucositis. 
Mouthwash for the treatment of 
ventilator-associated pneumonia. 
3 
 
3 
Ardea Biosciences / 
national Cancer 
Institute.  
IntraBiotics 
Pharmaceuticals. 
PAC-113 (P-113) a 
synthetic derivative of  
histatin 3 and  
histatin 5. 
Oral gel for the treatment of 
candidiasis 
 Pacgen  
Biopharmaceuticals 
 
Omiganan (MBI 226, 
MX-226, CSL-001), an 
analogue of indolicidin. 
 
 
Topical cream for the treatment of 
skin antisepsis, prevention of 
catheter infections / Rosacea. 
Topical cream for the treatment of 
usual type vulvar intraepithelial 
neoplasia / moderate to severe 
inflammatory acne vulgaris / mild to 
moderate atopic dermatitis. 
3 
 
 
3 
Mallinckrodt / 
Cutanea Life 
Sciences, Inc. 
Cutanea Life 
Sciences, Inc. 
 
OP-145, a derivative of 
LL-37. 
Ear drops for treatment of chronic 
bacterial middle-ear infection. 
2 OctoPlus  
hLF1Ȯ11, a derivative of 
lactoferrin. 
Intravenous administration for 
treatment of neutropenic stem cell 
transplantation patients. Prevention 
of bacteraemia and fungal infections. 
1/2 AM Pharma. 
Brilacidin, (PMX-30063), 
a defensin mimetic. 
Intravenous administration for 
treatment of acute bacterial skin and 
skin structure Infection caused by 
Gram-positive bacteria, including 
methicillin-resistant Staphylococcus 
aureus (MRSA). 
Oral rinse for the treatment of 
ulcerative mucositis associated with 
chemo / radiation therapy of cancer. 
3 
 
 
 
 
2 
Cellceutix. 
 
 
 
 
Cellceutix. 
Arenicins, naturally 
occurring AMPs. 
For the treatment of infections due to 
MDR Gram-positive bacteria. 
Preclin
ical 
Adenium Biotech  
Novexatin (NP213), a 
synthetic AMP. 
Brush on treatment for fungal 
infections of the toenail.  
1/2 NovaBiotics  
C16G2, a synthetic 
specifically targeted 
AMP. 
Mouthwash for the treatment of 
tooth decay caused by Streptococcus 
mutans 
2 C3 Jian, Inc. 
Lytixar (LTX-109), a 
peptidomimetic. 
Topical antibiotic for the treatment of 
nasal carriers of MRSA. 
Topical cream for the treatment of 
infections due to Gram-positive 
bacteria.  
1/2 
 
2 
Lytix Biopharma. 
 
Lytix Biopharma. 
Pharmaceuticals 2016, 9, x 
 
 
Table 2 was derived from [12-15] 71 
 72 
In order to develop AMPs as medically relevant anti-infective agents, there have been numerous 73 
investigations into their antimicrobial mechanisms, which to date has shown that membrane 74 
interaction is a requirement for virtually all of these mechanisms [9,10,16,17]. These investigations 75 
have also shown that there are a number of major drivers in the membrane interactions of AMPs of 76 
which the most important are charge, hydrophobicity and amphiphilicity [9,18,19]. The vast majority 77 
of AMPs are cationic to help facilitate the targeting of microbes through direct electrostatic interaction 78 
with anionic components of their membranes [19,20]. Nearly all AMPs are also amphiphilic, which 79 
generates hydrophobic surfaces that are able to drive the partitioning of these peptides into microbial 80 
membranes and hydrophilic surfaces that are able to stabilize these hydrophobic interactions via 81 
electrostatic associations with the head group regions of these membranes [21,22]. Based on these 82 
investigations, a variety of models have been proposed to describe the antimicrobial action of AMPs 83 
with those most frequently reported appearing to be variants of the barrel stave pore and carpet type 84 
mechanisms, which involve membrane disruption via discrete channel formation and non-specific 85 
solubilisation respectively [23].  86 
There have been many advances in understanding the mode of action used by AMPs but 87 
although a number of earlier studies showed that pH can modulate the antimicrobial activity of these 88 
peptides, no major review of this area of research appears to have been presented in the literature 89 
[24-28]. However, it is now becoming increasingly clear that pH is a major driver in the membrane 90 
interactions and biological activity of not only many AMPs but also a number of antimicrobial 91 
proteins produced by eukaryotes (Table 3).To update on these antimicrobial molecules, here, we 92 
present an overview of recent progress in the understanding of their modes of action along with the 93 
development of their therapeutic and biotechnological potential.  94 
 95 
2. An overview of pH dependent peptides and proteins with antimicrobial activity 96 
In the 1980s and 1990s, a series of seminal studies, including work on the African clawed frog, 97 
Xenopus laevis, and a number of mammals, led to what many take to be the first major description of 98 
eukaryotic AMPs such as magainins, defensins and SAAPs [29]. However, in 1956, phagocytin from 99 
humans, rabbits, horses and guinea pigs was reported to exhibit non-membranolytic activity against 100 
a range of Gram-positive and Gram-negative bacteria that was enhanced by low pH [24,25]. The 101 
peptide was not characterised or further investigated and today, it is not even known as to whether 102 
phagocytin was rediscovered later and given an alternative name [30]. However, it would appear to 103 
be a matter of historical fact that what was most likely the first AMP to be reported from eukaryotes 104 
showed a pH dependent mode of action [24,25]. Since these earlier studies, it is now known that these 105 
peptides are produced by virtually all multicellular organisms [31,32] and that an increasing number 106 
of these molecules possess pH-dependent activity (Table 3).  107 
  108 
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Table 3. AMPs with pH dependent activity. 109 
Vertebrates AMPs Host organism Key references 
Fish Gaduscidin-1 and 
gaduscidin-2   
Gadus morhua [33,34] 
Amphibians Chensinin-1  Rana chensinensis [35,36] 
 Esculentin-2EM  Glandirana emeljanovi This work 
 Dermaseptin PD-3-7 Pachymedusa dacnicolor [37]   
Humans Phagocytin  [24,25] 
 Psoriasin  [38-40] 
 Ά-microseminoprotein  [41]. 
 LL-37   [42] 
 Hep-25 and hep-20  [43-48] 
 Histatins  [49,50] 
 Lactoferrin  [51] 
 DCD-1(L)  [52-54] 
 Kappacin A and kappacin B  [55,56] 
Rabbits Phagocytin  [24,25] 
 Platelet microbiocidal 
proteins  
 [57] 
 NP1 and NP2  [58,59] 
Horses Phagocytin  [24,25] 
Guinea pigs Phagocytin  [24,25] 
Mice CRAMP  [42] 
Cattle Lactoferricin B  [60,61]. 
Invertebrates AMPs Host organism Key references 
Marine Myticin C  Mytilus galloprovincialis [62,63] 
 KPS-1 Atrina pectinate [64]   
 Ci-PAP-A22 and Ci-MAM-
A24  
Ciona intestinalis [65-68]  
 Clavaspirin and clavanins  Styela clava [69-80] 
 Styelins Styela clava [72,73,81] 
Terrestrial Hebraein  Amblyomma hebraeum [82] 
 Amoebapores  Entamoeba histolytica [83-87] 
 Acanthaporin  Acanthamoeba culbertsoni [88] 
 Caenopores Caenorhabditis elegans [89-93] 
 110 
2.1. Fish 111 
Gaduscidin-1 (gad-1) and gaduscidin-2 (gad-2) were AMPs identified in the Atlantic cod, Gadus 112 
morhua and shown to be highly, constitutively expressed in immune-relevant tissues [94,95]. Low pH 113 
was found to enhance the activity of both peptides against Escherichia coli, which appeared to involve 114 
membrane interaction, but interestingly, although gad-1 and gad-Ř were predominantly ΅-helical at 115 
neutral pH, acid conditions led to a large decrease in the levels of ΅-helicity possessed by these 116 
peptides [33].  These results contrast with most ΅-helical AMPs where an enhanced capacity for 117 
membranolysis and antimicrobial activity is generally associated with increased levels of this 118 
secondary structure [96,97]. It was proposed that gad-1 and gad-2 each possessed a structural 119 
plasticity, which facilitated an appropriate balance between amphiphilic and mixed hydrophobic / 120 
hydrophilic structural features that promoted maximal levels of membrane interaction and 121 
antibacterial activity [33]. Gad-1 and gad-2 were found to be histidine rich AMPs and the enhanced 122 
capacity of these peptides for membranolysis and antimicrobial activity at low pH appeared to 123 
Pharmaceuticals 2016, 9, x 
 
 
involve these residues [33]. It is well established that histidine (pKa 6.5) is uncharged at physiological 124 
pH but fully positively charged at low pH, thereby enhancing the potential of AMPs for interaction 125 
with anionic membranes under acid conditions [50,98]. However, there also appeared to be a complex 126 
relationship between the level of histidine residues possessed by these AMPs and their pH dependent 127 
capacity for membrane interaction [33,34].  In response, molecular dynamic simulation studies were 128 
undertaken and predicted that the number of sequential histidine pairs contained by gad-1 and gad-129 
2 were important to their ability for membrane disruption [34].  These AMPs possess one and two of 130 
these histidine pairs respectively [94] and the N-terminal regions of both peptides, which included 131 
this motif, were preferentially located proximal to membrane channels with which gad-1 and gad-2 132 
were associated [34]. Based on the topology of the peptide-lipid interactions mediating the formation 133 
of these channels, it was suggested that the antimicrobial action of gad-1 and gad-2 may involve the 134 
use of a disordered toroidal pore type mechanism of membrane disruption [34,99,100].  135 
2.2. Amphibians 136 
Chensinin-1 is a histidine rich peptide produced by the frog, Rana chensinensis and recent 137 
studies showed that low pH enhanced the positive charge of the peptide [35] and thereby, its ability 138 
to kill Gram-positive bacteria, such as Bacillus cereus [36]. This antibacterial activity appeared to 139 
involve the adoption of an extended structure, similar to that of other AMPs that are rich in specific 140 
residues [101,102], which induced lysis of the B. cereus membrane [36]. Interestingly, the peptide 141 
showed no activity against Gram-negative bacteria [36,103], which appeared to involve high affinity 142 
binding between chensinin-1 and lipopolysaccharide (LPS) in the outer membrane of these bacteria 143 
[103]. Maximin H5 from the toad, Bombina maxima, was also recently found to be ineffective against 144 
Gram-negative bacteria due to high affinity binding to phosphatidylethanolamine (PE) in the 145 
cytoplasmic membrane (CM) of these organisms [104,105]. Similar PE mediated mechanisms have 146 
been proposed to mediate the resistance of microbes to other AMPs [104,105], supporting the growing 147 
view that receptors could play a variety of roles in the biological activities of these peptides [23,98,106-148 
108]. Esculentin-2EM (E2EM, previously gaegurin 4Ǽ is an ΅-helical peptide isolated from the frog, 149 
Glandirana emeljanovi (formerly Rana rugosa) KIM [109,110], that is able to kill protozoa, fungi, Gram-150 
positive bacteria and Gram-negative bacteria [110-112]. E2EM possesses a C-terminal cyclic region 151 
stabilized by a disulphide bond (Rana box) that is conserved across many ranid AMPs and helps 152 
stabilise pore formation by the peptide thereby promoting its antimicrobial action (Figure 153 
1)[109,110,112-115]. Several models have been proposed to represent pore formation by E2EM and 154 
the best supported by experimental evidence appear to be the toroidal pore and barrel stave 155 
mechanisms (Figure 1). Here we present data showing that the linear reduced form of E2EM (E2EM-156 
lin) possesses antimicrobial activity consistent with recent studies showing that the reduction of 157 
cysteine-stabilized AMPs to generate peptides with novel mechanisms of antimicrobial activity may 158 
form part of some innate immune systems [116,117]. Our results showed that E2EM-lin was active 159 
against both Gram-positive and Gram-negative bacteria and appeared to exhibit pH dependent 160 
antimicrobial activity, which parallels the molluscan cysteine stabilized AMPs, myticins, whose 161 
reduced forms were described above to show pH dependent antibacterial and antiviral action [62,63]. 162 
It was found that under the low pH conditions associated with the skin of frogs [118], E2EM-lin had 163 
a general ability to induce the lysis of both anionic and zwitterionic membranes, which was enhanced 164 
at higher pH (Table 4). These data clearly suggest that the C-terminal disulphide bond in the E2EM 165 
Rana box region does not play a major role in its ability for membrane pore formation (Figure 1), 166 
which supports earlier work [114,115]. In the case of DMPG, which is a key component of membranes 167 
within Gram-positive bacteria [119], E2EM-lin induced relatively low levels of membrane lysis at acid 168 
pH (< 25%). However, a shift to alkaline pH led to a large increase in the lytic activity of the peptide 169 
to circa 95%, which was accompanied by a correspondingly large increase in its ΅-helical content of 170 
circa 25% to give levels approaching 75% (Table 4). Previous studies have shown that E2EM-lin and 171 
EŘEM adopt highly similar ΅-helical structures in membranes and undergo oligomerization to form 172 
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pores [115,120]. Based on these data, we speculate that high pH may enhance the ability of E2EM-lin 173 
to lyse DMPG membranes by increasing the potential of the peptide for pore formation through an 174 
increased capacity for self-association. The segments of E2EM-lin involved in pore formation are 175 
strongly amphiphilic ΅-helices with wide hydrophobic faces that would be maximized by alkaline 176 
pH, promoting the potential for the mutual interactions involved in the formation of multimeric 177 
species (Figure 1). In the case of DMPE, which is often taken to represent the membranes of Gram-178 
negative bacteria [119], E2EM-lin induced high levels of membrane lysis at acid pH (60%). A move to 179 
alkaline pH led to a relatively low increase in the lytic activity of the peptide, which was around 25% 180 
and was accompanied by a decrease in its ΅-helical content of 20% to give levels of circa 30% (Table 181 
4). These data would seem to indicate that E2EM-lin uses a different mechanism of lysis in the case 182 
of DMPE membranes and it has previously been suggested that the peptide may adopt a number of 183 
lipid interactive forms [115]. The functional significance of our data is not fully clear but given the 184 
very high levels of membrane lysis induced by E2EM-lin at higher pH for each lipid investigated, 185 
biological relevance is suggested, which forms the basis of ongoing investigations.  186 
 187 
Table 4. The ΅-helical content and lysis levels of E2EM-lin 188 
Lipid pH Lysis (%) ΅-helicity (%) 
DMPS 6 17 30 
 8 63 49 
DMPG 6 23 51 
 8 94 73 
DMPC 6 52 45 
 8 73 15 
DMPE 6 60 49 
 8 83 31 
The levels of lysis exhibited by E2EM-lin were determined using a calcein release assay and the levels of ΅-189 
helicity shown by the peptide were measured using CD spectroscopy, all as previously described [105]. 190 
 191 
 192 
 193 
 194 
 195 
 196 
  197 
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Figure 1. Models for the membrane pore formation by E2EM 198 
 199 
Figure 1 was revised from [115] and Figure 1A shows models for pore formation by E2EM, which are 200 
the toroidal pore and barrel stave mechanisms (Table 1) and are the best supported experimentally. 201 
In both models, the N-terminal 23 residues of the peptide spans the bilayer and a glycine kink 202 
orientates the 7 residue, C-terminal Rana box region of E2EM to lie parallel to the membrane surface. 203 
In this orientation, the Rana box region of the peptide, which is a cystein stabilized macrocyclic 204 
structure, interacts with the lipid head-group region of the membrane and stabilises pore formation 205 
by E2EM [115].  The major difference between these models is that in the toroidal pore mechanism, 206 
the membrane leaflets deform to allow the lipid head-group region to remain in contact with the 207 
hydrophilic face of the E2EM membrane spanning region, which is not observed  in the barrel stave 208 
mechanism [23].  For clarity, two monomers of E2EM are shown in the schematic pore above but 209 
oligomers formed by between five and ten peptide molecules have been proposed [115,120]. Similar 210 
models of membrane interaction appear to apply to the linear reduced form of the peptide [115], 211 
which is represented in our studies as E2EM-lin. Figures 1B and 1C show two-dimensional axial 212 
projections [121] for the membrane spanning region and Rana box domain of E2EM, respectively, that 213 
are involved in pore formation by the peptide. In both cases, these segments for amphipilic ΅-helices 214 
with wide hydrophobic faces that our data suggest would be maximised by alkaline pH, thereby 215 
promoting the potential for the mutual interaction of E2EM monomers and the formation of 216 
multimeric species involved in pore formation. 217 
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In addition to cationic AMPS, anionic AMPs with pH dependent activity have also been reported 218 
for amphibians, such as dermaseptin PD-3-7, which was isolated from the frog, Pachymedusa 219 
dacnicolor [122]. In aqueous solution, the peptide showed an inherent propensity to adopt an extended 220 
conformation and self-assemble into amyloid fibrils in a reversible pH-controlled manner [37].  At 221 
low pH, dermaseptin PD-3-7 existed as amyloid-like Ά-sheet aggregates but at higher pH underwent 222 
morphological changes, which led to the formation of metastable amorphous aggregates in a manner 223 
that appeared to be mediated by deprotonation of the aspartic acid residues (pKa 3.9) and C-terminal 224 
carboxyl groups possessed by the peptide. These amorphous aggregates induced damage to cells of 225 
the insect, Spodoptera frugiperda, by an unidentified mechanism but showed no activity against E. coli 226 
and Bacillus subtilis [37].  Based on these observations, it was suggested that amyloid formation by 227 
dermaseptin PD-3-7 may act as a storage facility for the peptide similar to the depository function 228 
proposed for the amyloidogenesis of pituitary peptide hormones [123]. Triggered by an increase in 229 
pH, this storage facility would release a pre-formed, cytotoxic agent that contributed to the natural 230 
defence strategy of the host amphibian [37].  However, it is worthy of note that the peptide was only 231 
tested for activity against a small number of bacteria [37] and it is generally accepted that AMPs are 232 
promiscuous in their antimicrobial mechanisms [29,124] with amyloid-mediated antibacterial 233 
mechanisms increasingly being reported  [23,125]. Interestingly, more recent studies on dermaseptin 234 
PD-3-7 have shown that stereochemical modification of the peptideȂs second residue to form the 235 
diastereomer [d-Leu2] strongly influenced the pH-triggered, morphological changes involved in 236 
amyloid formation by dermaseptin PD-3-7, inducing a fundamental change in its superstructural 237 
organization that was related to differences between the conformational propensities of these epimers 238 
[126]. It was proposed by these latter authors that epimers of PD-3-7 may play a role as anionic AMPs, 239 
or defence molecules, in the innate immune system of P. dacnicolor [126] and a similar proposal has 240 
been made for the production of epimeric AMPs by other frogs and toads [9].  241 
 242 
2.3. Humans and other mammals  243 
Psoriasin ǻSŗŖŖA7Ǽ is a human, cystein stabilized ΅-helical protein [127] of the S100 family of 244 
signalling proteins [128-130] that is known to have a role in the antimicrobial defence of the skin, 245 
including serving as a multifunctional modulator of neutrophil activation [131,132]. The protein was 246 
investigated for antimicrobial activity and shown to kill E. coli using pH independent mechanisms 247 
that were primarily due to the depletion of Zn2+ [38,39] and more recently, the protein was identified 248 
in vaginal fluid, appearing to help protect the female genital tract from infection [40]. Psoriasin was 249 
also found to kill Baciillus megaterium but via the use of two different modes of action, which involved 250 
Zn2+ depletion at neutral pH but membrane pore formation and oligomerisation of the protein at 251 
low pH. This pore forming mechanism was not further investigated but evidence suggested that it 252 
was likely to show some similarities to a barrel-stave pore type mode of action [38,39]. It is interesting 253 
to note that psoriasin exhibits a number of structural and functional similarities to amoebapore A 254 
(Figure 2) [39,133], which is a pH dependent antimicrobial protein from the protozoa, Entamoeba 255 
histolytica that is discussed below [85]. In particular, psoriasin possesses a histidine residue in its C-256 
terminal region [127] similar to amoebapore A [86] and based on these similarities, it can be 257 
speculated that the enhanced action of psoriasin against B. megaterium at low pH may involve a 258 
histidine mediated increased ability for pore formation and oligomerisation. Ά-microseminoprotein 259 
(MSP), also named as PSP-94, is a human protein that is believed to have a protective role in prostate 260 
carcinogenesis due to its ability to suppress the growth of tumours although more recent studies have 261 
suggested that MSP may protect against prostate cancer by inhibiting fungal infection in this genital 262 
region  [134,135]. This suggestion was primarily based on recent work, which showed that the acid 263 
conditions of the vagina promoted the ability of MSP in post coital seminal plasma to kill Candidia 264 
albicans.  This antifungal activity appeared to involve lysis of the organismȂs membranes and to be 265 
mediated by a C-terminal fragment of MSP, which included a glutamic acid residue involved in the 266 
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ability of the protein to form coordinate bonds with Ca2+. It appeared that MSP coordination of Ca2+ 267 
at neutral pH inhibited the antifungal activity of the protein but at low pH, electrostatic interaction 268 
between the ion and the C-terminal glutamic acid of MSP (pKa 4.1) decreased, facilitating the ability 269 
of the protein to kill C. albicans. Porcine MSP appeared to use a similar pH dependent antifungal 270 
mechanism, suggesting that it may be a widespread innate immune factor active against C. albicans 271 
and possibly helping to explain the low sexual transmission rate of vulvovaginal candidiasis in 272 
humans [41]. C. albicans was also reported to be susceptible to the pH dependent activity of LL-37 273 
and its derivatives, KS-30, and RK-31, along with CRAMP [42], which is a murine homologue of LL-274 
37 [136]. It appeared that KS-30, and RK-31 were produced by the proteolytic cleavage of LL-37 in the 275 
low pH environment of human sweat and that these pH conditions enhanced the ability all the 276 
peptides tested to kill C. albicans via permeabilisation of the fungal membrane.  The use of animal 277 
models showed that although LL-37 and its derivatives were induced in murine skin in response to 278 
C. albicans infection, this induction did not confer subcutaneous resistance to the organism [42]. Based 279 
on these results, it was suggested that these peptides may be of primary importance in forming a 280 
barrier against fungal infections on the skin surface [42], given that the dysregulated production of 281 
LL-37 and its derivatives has been strongly associated with skin disease due to fungi and other 282 
microbes [137-139]. Hepcidin, (hep-25) is a human Ά-sheet hormone that has a well-established role 283 
in iron homeostasis [140] and has been shown to exhibit pH dependent antimicrobial activity [43]. In 284 
particular, acid conditions been shown to enhance the activity of hep-25 and several of its isoforms, 285 
such as hep-20, against the fungal pathogen, Candida glabrata [44], along with a range of Gram-286 
negative bacteria, such as Pseudomonas aeruginosa, and Gram-positive bacteria, including 287 
Enterococcus faecium [45,46]. Studies on E. coli suggested that the antibacterial action of these 288 
peptides involved membranolytic mechanisms which were enhanced under acid conditions due to 289 
the presence of histidine residues within their primary structure [47]. Based on these observations, it 290 
was suggested that with acidic pH, the increase in positive charge of histidine residues in hep-25 and 291 
hep-20 would promote their ability to target and lyse bacterial membranes, resulting in the death of 292 
the host organism [43]. Hep-20 has also been shown to be effective against drug resistant C. glabrata 293 
under the low pH and physiological conditions associated with the vagina, which led to the 294 
suggestion that the peptide may form the basis of novel therapeutics for the control of vaginal 295 
infections due to the organism [48]. Another group of human AMPs rich in histidine residues are the 296 
histatins (hst), which are salivary peptides with antiviral, antibacterial and antifungal activity [141-297 
146] and protecting the oral cavity from fungal pathogens appears to be to the primary role of these 298 
peptides [147,148]. The pH of the oral cavity is mainly governed by that of saliva, which has a range 299 
that generally varies between pH 5 and pH 8 [149,150] although significantly lower pH values can 300 
occur on the surface of teeth due to the metabolic activities of cariogenic microorganisms [151], which 301 
is able to promote the growth of fungi and form mixed species biofilms [152,153]. Low pH appears 302 
able to enhance the antifungal activity of hst-1, hst-3 [154] and hst-5 [49], which, for example, 303 
enhances the positive charge carried by hst-5 and facilitates its translocation into fungal cells to attack 304 
intracellular targets [49]. However, a detailed description of the antifungal activity of these peptides 305 
is lacking and a number of mechanisms have been proposed [141,143-146], such as complex formation 306 
with iron to interfere with the cellular metabolism of the metal in fungi, such as C. albicans [155]. 307 
Studies on human lactoferrin, which is a multifunctional iron-binding protein [156] found that low 308 
pH enhanced the ability of sub-lethal levels of the protein to kill C. albicans, through multiple 309 
mechanisms, including dissipation of the proton motive force (PMF) across the CM of the organism 310 
[51]. This pH effect was attributed to increased electrostatic interactions between the peptide and 311 
anionic components of the C. albicans membrane, thereby enhancing the ability of lactoferrin to 312 
partition into fungal CM and generate lesions associated with PMF dissipation and the peptideȂs 313 
antifungal action [51]. Sub lethal levels of lactoferrin  have also been shown to be effective against 314 
biofilms of P. aeruginosa  [157] and the protein was found able to synergise the activity of other 315 
antimicrobials against biofilms formed from P. aeruginosa and methicillin resistant Staphylococcus 316 
aueus (MRSA) [158,159]. It was proposed that this anti-biofilm activity was due to the iron-binding 317 
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properties of the protein [157] but this does not appear to be the only mechanism involved in this 318 
activity [160] and acidic pH is strongly associated with these sessile  microbial communities [161]. 319 
Lactoferricin B, which is a potent AMP derived from bovine lactoferrin [162], has also been shown to 320 
possess pH dependent antimicrobial activity, killing bacteria and C. albicans at low pH via 321 
mechanisms that appeared to involve membranolysis [60,61]. Low pH was also found to enhance the 322 
activity of platelet microbiocidal proteins, which were isolated from leporine platelets and showed 323 
activity against Staphylococcus aureus, E. coli, and C. albicans [57]. These results strongly supported the 324 
mounting evidence that platelets serve important multiple roles in host defence against infection, 325 
including the localized release of AMPs and other antimicrobial factors in response to microbial 326 
colonization and other stimuli [163]. The pH dependent antimicrobial mechanisms of platelet 327 
microbiocidal proteins were not further characterised but other studies showed that the antifungal 328 
and antibacterial activity of a number of these AMPs involved dissipation of the PMF across the 329 
cytoplasmic membrane of target organisms, which was able to synergise the activity of conventional 330 
antibiotics [164]. These results parallel those described above for human lactoferrin, allowing the 331 
speculation that low pH enhances the ability of some leporine platelet microbiocidal proteins to 332 
interact with membranes of C. albicans and generate lesions associated with PMF dissipation and the 333 
peptideȂs antifungal action. Other leporine AMPs shown to possess pH dependent activity are the 334 
defensins, NP1 and NP2, which were found to permeabilise the outer membrane of P. aeruginosa most 335 
efficiently at low pH although these peptides were ineffective against the organism under these pH 336 
conditions. These AMPs are present in leporine macrophages and it was suggested that this pH 337 
dependent membranolytic activity may synergise the antibacterial action of other defence molecules 338 
under the acid conditions associated with phagocytosis [58,59]. 339 
 340 
Figure 2. Similarities between the structures of psoriasin and amoebapore A 341 
 342 
Figure 2 was revised from [39] and shows human psoriasin (A) and amoebapore A from the protozoa, 343 
Entamoeba histolytica (B). It can be clearly seen that these peptides show structural similarities and 344 
both have been shown to possess pH dependent mechanisms of antimicrobial activity that is 345 
enhanced by acid conditions [38-40,83-85,87]. In particular, psoriasin possesses a histidine residue in 346 
its C-terminal region [127] similarly to amoebapore A [86] and based on these similarities, it can be 347 
speculated that the enhanced antibacterial action of psoriasin at low pH may involve a histidine 348 
mediated increased ability for pore formation and oligomerisation. 349 
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A particularly important case of human AMPs with activity that can be influenced by pH is that 350 
found in the airway surface liquid (ASL) of individuals with cystic fibrosis (CF) [165,166], which is a 351 
lethal genetic disorder characterized by viscous mucus and bacterial colonization of the airways 352 
[167]. In the mammalian respiratory system, the ASL represents a first line of pulmonary defence by 353 
forming the interface between the environment and the host organism and helping to protect against 354 
the action of inhaled and aspirated bacteria by producing a variety of antimicrobial molecules 355 
[168,169]. These ASL molecules include AMPs, such as LL-37, HNP-1, HBD-1 and lactoferrin, along 356 
with antimicrobial proteins, such as lysozyme, surfactant protein A and surfactant protein D 357 
[165,166]. Many of these antimicrobial molecules also contribute to the pulmonary innate immune 358 
system by adorning lattices of extracellular DNA, chromatin, enzymes and other proteins to form 359 
neutrophil extracellular traps (NETs). These DNA complexes are released in response to the presence 360 
of microbial pathogens and provide a mechanism for the localised concentration of effector 361 
molecules. NETs have been reported able to eradicate microbial pathogens using a variety of 362 
mechanisms, including the action of antimicrobial attachments and proteolytic degradation, as well 363 
as neutralizing their activity by forming a physical barrier that prevents the dissemination of these 364 
pathogens [166,170-172]. More recent studies have shown that the Human Short Palate Lung Nasal 365 
Epithelial Clone 1 (SPLUNC1), which is a protein expressed in the upper airways of the lung, plays 366 
multiple roles in pulmonary innate immunity. These roles include: the direct inhibition of bacterial 367 
growth, the prevention of microbial biofilm formation and the regulation of other AMPs and 368 
antimicrobial proteins, such as LL-37, HBD-2 and lysozyme [173-176]. However, in CF, mutations in 369 
the cystic fibrosis transmembrane conductance regulator (CFTR) gene leads to reduced HCO3− 370 
secretion and produces an abnormally acidic pH in ASL [177,178], which studies on humans and 371 
animal models have suggested can negatively affect the efficacy of ASL antimicrobial molecules and 372 
predispose CF airways to microbial infection (Figure 3) [165,179]. For example, recent studies on a 373 
porcine CF model showed that the low pH of the ASL inhibited the activity of LL-37, lactoferrin and 374 
other AMPs when directed against S. aureus and P. aeruginosa [180,181], which are known, major CF 375 
pathogens [182,183]. These acid conditions also reduced the ability of ASL AMPs to synergize their 376 
activities when in combination with each other and with antimicrobial proteins, such as lysozyme 377 
[180,181]. It has been further proposed that conditions of low pH in CF airways could reduce the 378 
efficacy of AMPs and antimicrobial proteins that adorn NETs [170] along with the antimicrobial and 379 
other biological activities of SPLUNC1 [179,184]. The mechanisms by which the low pH impairs the 380 
activity of AMPs and antimicrobial proteins in CF airways are currently unclear but it has been 381 
suggested that these mechanisms include a variety of contributions. For example, it has been 382 
proposed that low pH in CF airways may mediate the degradation of AMPs via the activation of host 383 
proteases, such as cysteine cathepsins, and microbial enzymes, such as aureolysin of S. aureus and 384 
elastase of P. aeruginosa, and the immobilization of AMPs through binding to mucins, which are large, 385 
anionic glycoproteins and the primary component of mucus. It has been further proposed that low 386 
pH in CF airways may induce conformational changes in AMPs that reduce the ability of these 387 
peptides to bind microbial membranes and cell wall components, such as lipid II 388 
[165,166,170,180,181,185]. In addition to reducing the activity of AMPs, low pH appears able to 389 
negatively impact on other defence factors of the ASL; for example, by increasing the rheological 390 
properties of secreted mucins, decreasing ciliary beat frequency, impairing phagocyte function and 391 
depleting ASL volume [165,166,179,185]. Based on these observations, it has been proposed that 392 
connections between the loss of CFTR, reduced ASL pH, and impaired CF host defense function 393 
could provide a paradigm for the identification of new therapeutic targets and strategies to reduce 394 
the morbidity associated with CF lung disease [165]. 395 
 396 
  397 
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Figure 3.  The pH of airway surface liquid and the pathogenesis of cystic fibrosis 398 
 399 
Figure 3 was revised from [165] and shows a scheme for how changes in ASL pH may influence the 400 
pathogenesis of CF. In CF, the loss of CFTR function results in decreased HCO3− conductance across airway 401 
epithelial cells and leads to low pH in the ASL. Under these pH conditions, ASL AMPs, such as LL-37, 402 
HNP-1, HBD-1 and lactoferrin, and antimicrobial proteins, such as lysozyme, surfactant protein A and 403 
surfactant protein D, have reduced activity. Lower pH also leads to the increased viscosity of mucins, 404 
decreased ciliary beat frequency, impaired phagocyte function and depleted ASL volume. These effects 405 
lead to a decrease in the antimicrobial efficacy of the ASL and subsequently contribute to increased 406 
respiratory infections in the CF airway, caused by both viral and bacterial pathogens [165,166,179,185]. 407 
 408 
A number of anionic AMPs with pH dependent activity have been identified in humans, 409 
including DCD-1(L), which is proteolytically cleaved from dermcidin, which is also an anionic 410 
peptide and found in human sweat [9,52,186,187]. DCD-1(L) is characterised by its broad range 411 
antimicrobial activity, killing fungi, such as C. albicans, as well as Gram-positive bacteria, including 412 
MRSA, Gram-negative bacteria, such as Salmonella typhimurium, and acid fast bacteria including 413 
rifampin- and isoniazid-resistant Mycobacterium tuberculosis [188-193]. The peptide appears to exhibit 414 
pH dependent antibacterial action [188] whereby low pH induces the peptide to adopt ΅-helical 415 
structure on the bacterial membrane surface, leading to ion channel formation via Zn2+ stabilized 416 
DCD-1(L) oligomers and death of the host organism through membrane disruption [52,53]. A more 417 
recent study gives general support to this model and suggested that under acid conditions, the 418 
negative charge on DCD-1(L) becomes neutral, which facilitates membrane partitioning and Zn2+ 419 
dependent membrane channel formation via either a barrel-stave pore or a toroidal pore type 420 
mechanism [54]. Another example of AAMPs with pH-dependent activity are kappacin A and 421 
kappacin B, which are classed as food peptides and appear to be cleaved from -casein in bovine milk 422 
by digestion with chymosinin in the human stomach [194]. These peptides exhibit potent activity 423 
against a range of Gram-positive and Gram-negative bacteria, including Streptococcus mutans, 424 
Porphyromonas gingivalis and Actinomyces lundii [55,56], which make a major contribution to 425 
supragingival dental plaques [195,196]. Characterisation studies showed that the antibacterial 426 
mechanisms used by kappacins involved the pH-dependent lysis of microbial membranes, which 427 
was enhanced by acid conditions [56]. The active region of kappacins included a phosphorylated 428 
serine residue that was essential for antibacterial activity [56,197] and interestingly, these peptides 429 
showed significantly different pH optima for this activity that resulted from a single residue 430 
difference in the sequence of their active regions [55,197]. Kappacin A showed the highest 431 
antibacterial activity of the two peptides and possessed an aspartic acid residue in its active region, 432 
which was replaced by an alanine residue in the corresponding location of kappacin B [55,197,198]. 433 
The functional significance of this difference in sequences is not known although it has been proposed 434 
that the additional negative charge possessed by kappacin A may enhance its ability to bind metal 435 
ions [9]. It had been demonstrated that the presence of Ca2+ and Zn2+ ions enhanced the antibacterial 436 
activity of kappacins  and it was suggested that these ions may form a cationic salt bridge between 437 
kappacins and anionic components of the bacterial membrane, thereby facilitating membrane 438 
binding and antibacterial action [197]. It has been proposed that the membrane interactive 439 
conformation of these peptides may be a proline-kinked amphiphilic ΅-helix but conformational 440 
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changes observed in the peptide in the presence of membrane mimic could not be clearly assigned to 441 
any particular secondary structures and the structure of kappacins remains unclear [9,56,197,198].  442 
 443 
2.4. Marine invertebrates 444 
Myticin C (myt C) exists as a number of isoforms in the bivalve mollusc, Mytilus galloprovincialis 445 
[199-201] and has been shown to possess activity against fish viruses, including Hemorrhagic 446 
Septicaemia virus and Infectious Pancreatic Necrosis virus [202]. Several studies were conducted on 447 
the antimicrobial activity of a reduced form of myt C, (myt Cc, [62,63]) based on the proposal that the 448 
endogenous reduction of cysteine-stabilized AMPs to produce peptides with higher levels of 449 
antimicrobial activity may form part of some innate immune systems [116,117].  It was found that the 450 
antiviral activity of myt C, myt Cc and derivatives of both these peptides was enhanced by low pH. 451 
These studies also showed that only under acid conditions did these various peptides possess activity 452 
against Gram-positive bacteria and Gram-negative bacteria. Structure function studies on E. coli 453 
suggested that the antimicrobial action of myt C and its variants was membranolytic and involved 454 
low pH mediated increases in their levels of ΅-helicity and Ά-hairpin elements within their molecular 455 
architecture [62,63]. In addition to their pH dependent antimicrobial activity, both myt C and myt Cc 456 
possessed chemotactic activity and appeared to be the first chemokine/cytokine-like molecules 457 
identified in bivalves [63,202]. These results added to the increasing evidence that AMPs can serve as 458 
cytokines [29,203] and interestingly, it is also becoming clear that these latter peptides are able to 459 
exhibit antimicrobial activity [204,205] that is enhanced by low pH [206,207]. Molluscs are also a 460 
source of histidine containing AMPs with pH dependent activity, such as the peptide, KPS-1, which 461 
was isolated from, Atrina pectinate, and under acid conditions, inhibited the growth of a range of 462 
Gram-negative bacteria, including P. Aeruginosa, S. typhimurium and Enterobacter sakazakii [64]. Ci-463 
PAP-A22 and Ci-MAM-A24 are representative peptides of the Ci-PAP and Ci-MAM families of 464 
AMPs from the solitary tunicate (Sea squirt), Ciona intestinalis [65,66], which appear to be produced 465 
in haemocytes and granulocytes of the organism. [208,209]. Both peptides were found to be 466 
predominantly ΅-helical and to possess antimicrobial activity [68,209,210] that appeared to have a 467 
pH dependency with optima that varied according to the target microbes [65-68].  In the case of Ci-468 
PAP-A22, the activity of the peptide against fungi, Gram-negative and Gram-positive bacteria was 469 
enhanced by neutral pH except for B. megaterium which was more efficiently killed by Ci-PAP-A22 470 
at acid pH [65]. In contrast, Ci-MAM-A24 showed enhanced activity against B. megaterium, B. subtilis, 471 
E. coli and P. aeruginosa at low pH but neutral pH optima for action towards S. aureus, Staphylococcus 472 
epidermis, Serratia marsecens and Klebsiella pneumoniae.  The peptide was also found to exhibit pH 473 
independent antimicrobial activity, killing comparable levels of Yersinia enterocolitica and fungi under 474 
low and neutral conditions of pH [66]. The antimicrobial activity of both Ci-PAP-A22 and Ci-MAM-475 
A24 appeared to involve a membranolytic mechanism that had characteristics consistent with a 476 
ȁcarpetȂ or ȁtoroidal pore, type model (Table 1). To help explain the differences in pH dependent 477 
antimicrobial activity shown by these peptides it was suggested that histidine mediated variation in 478 
their positive charge may facilitate optimal membrane interaction on a species- specific basis [65,66] 479 
and of course varying lipid composition will mean differing bacterial systems exhibit different 480 
changes to key parameters such as lipid packing at varying pH. Interestingly, Ci-MAM-A24 was 481 
found to be more potent than Ci-PAP-A22 and appears to be the first AMP reported to kill an intra-482 
amoebic pathogen [67]. It was demonstrate that Ci-MAM-A24 was able to kill Legionella pneumophilia, 483 
which is a Gram-negative parasite responsible for LegionnaireȂs disease [211], whilst the organism 484 
was replicating intracellularly in Acanthamoeba castellani [67]. It is well established that A. castellani 485 
acts as a vector for this bacterium [212,213], which efficiently replicates in the acidic environment of 486 
host amoebal phagosomes [214,215]. Ci-MAM-A24 was also able to kill Mycobacteria, in murine 487 
macrophages [210] and these acid fast bacteria are known to replicate  in the acidic compartments of 488 
these host cells [216]. Given the pH dependent antimicrobial activity of the peptide, it is tempting to 489 
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speculate that the ability of Ci-MAM-A24 to kill these various bacterial parasites was potentiated by 490 
the low pH of their host cell environments. Clavaspirin, clavanins and styelins were isolated from 491 
another solitary tunicate, Styela clava and these pH dependent AMPs were found to be rich in both 492 
histidine and phenylalanine residues [72,73]. In general, it was found that clavaspirin and clavanins 493 
possessed pH dependent antibacterial and antifungal activity [69-71,80] with low pH enhancing the 494 
ability of these AMPs to adopt ΅-helical structure and permeabilize the membranes of these 495 
organisms [72,73]. It appeared that the protonation of histidine residues under low pH conditions 496 
promoted the ability of these AMPs to target microbial membranes whilst the presence of their 497 
glycine and phenylalanine residues provided them with the conformational flexibility and structural 498 
hydrophobicity to facilitate bilayer partitioning [74-79]. Styelins, which are rich in phenylalanine 499 
residues, were found to show activity against both human bacterial pathogens and marine bacteria, 500 
such as Psychrobacter immobilis and Planococcus citreus, [72,217]. The best characterised of these AMPs 501 
is styelin D, which possesses ΅-helical structure and is highly unusual in that it contains twelve post-502 
translationally modified residues [81]. For example, the peptide contained multiple 503 
bromotryptophan residues, which are found in the AMPs of other marine organisms [218-222] and 504 
play an important role in the life of sea sponges and lower marine invertebrates [223]. Styelin DȂs 505 
post-translationally modified residues enhanced the peptideȂs membranolytic action at low pH but 506 
only against Gram-positive bacteria. It was suggested that a role for these extensive modifications 507 
may be in preserving activity against certain organisms under the acid conditions found in 508 
haemocytes of S. clava where the styelins are active [81].  509 
 510 
 511 
2.5. Terrestrial invertebrates 512 
Hebraein is produced by the tick, Amblyomma hebraeum [224] and showed acid pH optima for its 513 
activity against E. coli, S. aureus and the fungus, C. glabrata [82], a major cause of vulvovaginal 514 
candidiasis in diabetics [225]. The peptide possessed an ΅-helical structure except for a short C-515 
terminal extension containing multiple histidine residues, which appeared to be required for activity 516 
against these organisms [82]. Based on these observations, it was suggested that the acidic pH 517 
induced in the physiological environment when a tick blood-feeds would increase the cationicity of 518 
hebraein and thereby its membrane interactivity and antimicrobial potency [82]. However, the 519 
activity of hebraein against S. aureus appeared to be independent of this histidine cluster and C. 520 
albicans was not susceptible to the action of the peptide suggesting that it possessed a variety of 521 
antimicrobial mechanisms, which were influenced by the target organism [82]. Interestingly, these 522 
latter studies showed hebraein to possess homology and structural similarities to microplusin, which 523 
is a Cu2+ chelating peptide isolated from another arachnid, the cattle tick, Riphicephalus microplus, with 524 
broad range antimicrobial activity [226-228]. Studies on the Gram-positive bacterium, Micrococcus 525 
luteus, and the fungus, Cryptococcus neoformans, suggested that Cu2+ chelation involving histidine 526 
residues promotes the antimicrobial activity of microplusin by depriving vital cellular processes of 527 
the ion, such as haeme-copper terminal oxidases that contribute to cell respiration [228-230]. 528 
Amoebapores are a family of cystein stabilized antimicrobial proteins with ΅-helical structures that 529 
are found in the cytoplasmic granules of the protozoan parasite of primates, Entamoeba histolytica 530 
[83,85,231], and interestingly there is evidence to suggest that amoeba-like peptides may have been 531 
amongst the first eukaryotic AMPs to emerge [232].  Amoebapore A is the best characterized of this 532 
family of proteins and has been shown to exhibit pH dependent activity against Gram-positive 533 
organisms, such as M. luteus, and Gram-negative bacteria, including E. coli [83,84,87], which appears 534 
to involve pore formation in the membranes of target organisms [84].  Both pore formation and the 535 
antibacterial activity of the protein were enhanced by low pH, which appears to derive from an 536 
increased ability of amoebapore A to self-associate and form oligomers with some similarities to a 537 
barrel-stave pore type mode of action [83-85]. Elucidation of the structure of amoebapore A indicated 538 
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that a C-terminal histidine residue acted as a molecular switch that triggers the formation of active 539 
dimers from inactive monomers, which leads to the construction oligomeric pores in target cell 540 
membranes,  [86]. In addition to amoebapore A, two isoforms of the protein, amoebapores, B and C, 541 
are included in the amoebapore family and all three isoforms differ markedly in their primary 542 
structure and spectra of antibacterial activity, synergising their combined efficacy. Amoebapores, B 543 
and C are believed to have similar antibacterial mechanisms to amoebapore A and the acidic pH 544 
optima of these proteins is consistent with the low pH conditions encountered in the 545 
amoebic intracellular vesicles, which form their site of action [83,85,231]. More recently, 546 
acanthaporin, which is another protozoan protein with pH dependent antimicrobial activity was 547 
described in the Acanthamoeba culbertsoni. At neutral pH, acanthaporin appears to exist as an inactive 548 
dimer but low pH triggers the histidine mediated production of monomers and the formation of 549 
membrane pores, which promoted the activity of the peptide against a variety of bacteria [88]. 550 
Caenopores, also known as saposin-like proteins (SPP), are cystein stabilized helical proteins that are 551 
found in the nematode, Caenorhabditis elegans [93,232-235] and are distantly related to amoebapores 552 
with which they share structural and functional features [89,92,236,237].  Many of the genes encoding 553 
SPP proteins in C. elegans are induced in response to microbial challenge [232] and  several of their 554 
gene products have been reported to exhibit pH dependent antimicrobial activity, including SSP-1 555 
[89,90], SPP-3 [91], SPP-5  [92] and SPP-12 [90]. These studies showed that that low pH enhanced the 556 
ability of caenopores to kill a wide range of microbes, including Gram-negative bacteria, such as E. 557 
coli; Gram-positive bacteria, including Bacillus thuringiensis; yeasts, such as Saccharomyces cerevisiae; 558 
and amoebae, including Dictyostelium discoideum. For each of these proteins, antimicrobial activity 559 
appeared to be based on an ability to form pores in membranes of target organisms under acid pH 560 
conditions and it was suggested that this ability was mediated by the multiple internal 561 
histidine residues possessed by caenopores. Due to these residues, the positive charge of these 562 
proteins is enhanced under acid conditions, increasing the potential for interaction with anionic 563 
components of microbial membranes and possibly mediating pore formation, as described for 564 
amoebapores [90-93,236,237]. It was observed that the pH dependent activity of these proteins would 565 
appear to reflect the pH conditions at the site of their functional action, such as SPP-1 and SPP-5, 566 
which are active in the acidic environment of the C. elegans intestine [92,93,236,237]. 567 
 568 
3. Potential applications of pH dependent antimicrobial peptides and proteins  569 
In response to the growing demand for new antibiotics with novel mechanisms of action, the 570 
number of AMPs and antimicrobial proteins entering clinical trials is accelerating [12] and included 571 
within these antimicrobial molecules are a number that have been reviewed here (Table 2). Currently, 572 
the only pH dependent anionic AMPs that appear to have been commercially developed are 573 
kappacins. Based on their activity against oral pathogens [55,56], preparations including these 574 
peptides and zinc have been patented [238] and are available as a dental care products [194,198]. It 575 
has also been shown that these peptides exhibit increased antimicrobial activity in foods with high 576 
calcium contents [194], which, taken with the history of the safe use of -casein, led to the proposal 577 
that kappacins may be used as a preservative [239]. In the case PD-3-7, epimers of this peptide appear 578 
to be the only amyloid forming amphibian anionic AMPs so far reported and have the potential to 579 
progress understanding of the role of residue chirality in the formation of disease-related amyloid 580 
and aid the design of amyloid-based nanomaterials [126]. The development of functional amyloids 581 
as novel nanostructure materials for multiple purposes, such as drug delivery and tissue repair / 582 
engineering, is a growing area of technology [240,241] and recently, techniques have been developed 583 
to detect epimeric AMPs in the complex skin secretions of frogs and toads [242].  584 
The most researched of the cationic AMPs reviewed here for potential medical development is 585 
LL-37, which is a prospective broad range antimicrobial agent that is also able to induce wound 586 
healing and angiogenesis as well as modulate apoptosis [243]. This potential is though limited in 587 
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some cases by the pleiotropic effects of the peptide [244]. For example, the peptide shows a variation 588 
in its sensitivity to cancer types, promoting proliferation, migration, and tumorigenesis in breast, 589 
lung, and prostate cancers through receptor signaling but suppresses proliferation and induces 590 
apoptotic and autophagic cell death in gastric cancer, colon cancer, and T-cell leukemia [107]. 591 
However, wound treatment is a globally prevalent and economic burden, which makes the 592 
pleiotropic ability of LL-37 to exert healing properties and combat multiple microbial pathogens an 593 
attractive platform that has been used to develop potential therapeutic strategies for wound 594 
treatment [245]. For example, a clinical phase I/II study conducted by Pergamum on LL-37 led to a 595 
patent [246] and showed that topical application of the peptide was safe and enhanced wound 596 
healing in patients with chronic venous leg ulcers and diabetic patients suffering from infected 597 
wounds [245,247]. Wound infection is a major complication in diabetic patients and in particular, 598 
infected foot ulcers is one of the most serious and frequent of these complications, which accounts 599 
for over 50% of all lower limb amputations performed on these patients [248]. More recently, several 600 
studies have developed biodegradable drug delivery system that facilitated the controlled sustained 601 
release of LL-37 and other wound healing agents, such as lactate and serpin A1, from nanoparticles. 602 
LL-37 and these agents acted synergistically in the treatment of full thickness excisional wounds, 603 
significantly promoting wound closure, reducing bacterial contamination and enhancing anti-604 
inflammatory activity. These systems offered several advantages over therapies commonly used to 605 
treat chronic wound infections, which are often limited due to factors, such as the lack of controlled 606 
delivery and the depth of skin infections [249,250]. A number of LL-37 related peptides have also 607 
shown the potential for therapeutic development [243,251], such as OP-145, which was developed by 608 
OctoPlus, and when the peptide was included in cream formulations for nasal application, these 609 
preparations were found to be efficacious in the eradication of MRSA carriage [252]. The anterior 610 
nares are the main reservoir for colonization by S. aureus and the nasal carriage of MRSA is an 611 
important risk factor for subsequent infection and transmission of this pathogen, which has led to 612 
intensive efforts to identify agents able to efficiently reduce MRSA colonization [253]. The completion 613 
of phase I/II clinical trials by OP-145 also showed that the peptide was safe and efficacious as a 614 
treatment for chronic otitis media, or chronic bacterial middle-ear infection (Table 2) [254]. This 615 
disease afflicts millions of people worldwide and is highly recalcitrant to treatment by conventional 616 
antibiotics, which is now known to be primarily due to bacterial biofilms [255]. Another derivative 617 
of LL-37, 60.4Ac, has also proven to be beneficial in the treatment of patients with otitis media [245] 618 
and more recently the peptide showed the potential for development as a novel local therapy to treat 619 
patients with burn wounds infected with multidrug-resistant bacteria, including MRSA [256]. Burn 620 
wounds are one of the most common and devastating forms of trauma and the infection of these 621 
wound by drug resistant bacterial pathogens is rapidly becoming a serious therapeutic challenge in 622 
the care of burn patients [257]. 623 
Histatins and their derivatives show the potential for a wide range of therapeutic and 624 
biotechnical application [141], particularly in the field of dentistry and bio-dental research [258]. For 625 
example, the hst-5 derivative, JH8194, is a promising candidate to act as a surface substrate in dental 626 
implants to prevent peri-implantitis and peri-implant mucositis whilst decreasing infections 627 
[259,260]. A major focus in the medical development of histatins has been in the preparation of 628 
formulations to treat oral diseases and infections [141]. For example, highly effective hydrogel 629 
delivery systems for the topical and oral application of hst-5 have been developed for the treatment 630 
of oral candidiasis [261], which is the most common opportunistic fungal infection in 631 
immunocompromised populations [262]. High potential for the topical treatment of this fungal 632 
condition was also demonstrated when derivatives of hst-5 were conjugated to spermidine and tested 633 
on immunocompromised murine models [263]. Compared to hst-5, these conjugates exhibited a 634 
higher clinical half-life, enhanced uptake into Candida cells, and greater candidacidal efficacies, and 635 
were proposed to be viable alternatives to azole antifungals [263], which are commonly used to treat 636 
oral candidiasis [262]. A compound derived from hst-5 and hs1-3, P-113 (PAC-113), developed by 637 
Pacgen, was evaluated in Phase 1/ II clinical studies for the treatment of both oral candidiasis and 638 
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gingivitis, and was found to be safe and effective in the treatment of both conditions (Table 2)[12]. 639 
Gingivitis is the most common form of periodontal disease, affecting up to 15% of the adult 640 
populations worldwide and primarily due to Porphyromonas gingivalis. Untreated the condition can 641 
lead to periodontitis, the chronic destruction of connective tissues, and ultimately result in loss of 642 
teeth [264]. P-113 has been patented [265] and most recently, it has been shown that the candicidal 643 
efficacy of the peptide was greatly enhanced when it was modified by coupling to other AMPs and 644 
their derivatives [144] Another histatin, hist-1, was conjugated to a silver metallopharmaceutical and 645 
the conjugate was found to have wound healing properties coupled to potent activity against 646 
bacteria, which included MRSA, indicating the potential for development of novel multifunctional 647 
therapeutics [266]. Clavanins are attractive candidates for development as drugs against bacteria 648 
associated with sepsis, which is rapidly becoming a problematic nosocomial infection [267], and 649 
recently developed nanoparticle formulations of these peptides, showed high promise as a drugs 650 
against polymicrobial sepsis with morphological characteristics suitable for administration via 651 
injection [80] . Derivatives of clavanins have also been developed to combat biofilms formed by, S. 652 
mutans, which is a major contributor to dental plaque and one of the major etiological factors involved 653 
in causing caries [268]. Dental caries is one of the most prevalent, preventable infectious diseases 654 
affecting humans and is recognized as the primary cause of oral pain and tooth loss [269]. 655 
The major medical development of the antimicrobial proteins reviewed here appears to be 656 
lactoferrin, which as described above is an iron binding protein but, like LL-37, is pleiotropic and also 657 
displays broad range antimicrobial activity using a number of mechanisms, which includes the 658 
release of derivative AMPs via hydrolysis by proteases [162,270,271]. Lactoferrin and its related 659 
peptides shows the potential for a number of clinical uses, ranging from wound healing and the 660 
detection of bacteria to the treatment of microbial infections both alone and in combination with other 661 
clinically relevant agents [272]. A full description of these medical uses is beyond the scope of this 662 
review but lactoferrin and its derivatives have featured in multiple clinical trials [160,272,273] and 663 
have numerous entries in a recently constructed database of bioactive peptides derived from milk 664 
proteins [274]. As major examples, lactoferrin and its derivatives have been extensively investigated 665 
as potential drugs for the treatment of common viral infections including the common cold, influenza, 666 
viral gastroenteritis and herpes  [275] whilst the inhibitory effects of these proteins and peptides 667 
against the proliferation of multiple cancers, has suggested a potential role in cancer prevention [276]. 668 
It is well established that many AMPs and antimicrobial proteins have anticancer activity that 669 
generally appears to involve mechanisms of membranolysis that are similar to those used by these 670 
molecules in their action against microbes [277,278], which in some cases shows pH dependence [98], 671 
as recently described [279,280]. Advanced clinical trials have shown that the administration of 672 
lactoferrin has no significant side effects and that the protein has efficacy in treating iron deficiency 673 
anemia in pregnant women [281], sepsis in premature neonates, which is a common and severe 674 
complication in new-born infants [282] and infections due to Helicobacter pylori, which is causally 675 
associated with gastritis and peptic ulcer diseases [283]. A major example of the medical potential of 676 
lactoferrin is the development of ALX-109 by Alaxia, which is a combination of the protein and 677 
hypothiocyanite for the treatment of CF [160]. This drug combination has been granted orphan drug 678 
status by American and European licensing agencies and has been shown to enhance the ability of 679 
conventional antibiotics to eliminate biofilms of P. aeruginosa growing on CF airway epithelial cells 680 
[284]. Derivatives of lactoferrin, have also shown the potential for therapeutic development such as 681 
hLF(1-11), which was developed by AM Pharma, and in clinical trials the peptide was safely injected 682 
into neutropenic stem cell transplantation patients [160]. Neutropenia is defined as a reduction in the 683 
absolute number of neutrophils in the blood circulation, predisposing individuals to severe or fatal 684 
infections [285], and currently, hLF(1-11), awaits development  for the prevention of bacteremia and 685 
fungal infections in immunocompromised individuals (Table 2)[273].  Lactoferricin B is cleaved from 686 
the N-terminal region of bovine lactoferrin under acid pH conditions and has an extremely wide 687 
spectrum of antimicrobial activity against bacterial, fungal and parasite species as well as showing 688 
anti-catabolic and anti-inflammatory effects [162,270,271]. Based on these abilities, this peptide has 689 
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featured in numerous preclinical trials and shows the potential for a variety of therapeutic purposes, 690 
including the treatment of ocular infections, osteo-articular gastro-Intestinal and dematological 691 
diseases, along with applications in veterinary practice and the food industry [272]. The commercial 692 
importance of lactoferrin and its derivatives is perhaps underlined by the fact that the recombinant 693 
human protein has been expressed in transgenic cattle to provide the large-scale production of 694 
lactoferrin for pharmaceutical use [286]. The recombinant protein has also been expressed in microbes 695 
and higher plants in the search for bioreactors with the capacity for large-scale production, which, 696 
led to lactoferrin expression also being used as a tool for the enhancement of plant resistance to 697 
pathogens [286]. 698 
 699 
4. Discussion 700 
AMPs and antimicrobial proteins with pH dependent action against microbes appear to receive 701 
relatively little attention in the literature but, as this review has shown, these molecules are produced 702 
by a diverse spectrum of eukaryotes, including: vertebrates, such as fish, humans, horses, cattle, 703 
rabbits, guinea pigs, mice, frogs and toads, as well as invertebrates, such as ticks, parasites, worms 704 
and mollusks (Table 3). Around two thirds of the molecules reviewed here are cationic AMPs and 705 
antimicrobial proteins with most of those that remain possessing net negative charges [287]. It is 706 
generally recognized that the incidence of anionic antimicrobial molecules is low and that, in general, 707 
their occurrence appears to be a strategy to synergize the antimicrobial activity of their cationic 708 
counterparts [9,288]. For example, the proteolytic processing of the sweat borne peptide, dermcidin, 709 
to yield DCD-1(L), described above, also produces a number of other anionic AMPs, such as SSL-46 710 
(net charge Ȯ2) and LEK-45 (net charge -2) [289]. These sweat-derived anionic AMPs are continually 711 
secreted and are believed to synergize the activity of cationic AMPs in the constitutive innate defense 712 
of human skin by modulating surface colonization by microbes rather than responding to injury and 713 
inflammation as observed for inducible peptides, such as LL- 37 [186]. 714 
The pH dependence of the antimicrobial molecules reviewed here was found to vary with pH 715 
with some, such as E2EM-lin, exhibiting high pH optima (Table 4) whilst others, such as Ci-PAP-A22 716 
and Ci-MAM-A24, exhibited optima at either neutral or acid pH depending on the target organisms 717 
[65-68]. Again depending on the target microbes, several antimicrobial molecules, including the latter 718 
peptides and psiorasin, showed the ability to employ both pH dependent and pH independent 719 
activity [38-40,65-68]. However, most of the AMPs and antimicrobial proteins reviewed here 720 
exhibited low pH optima, which is consistent with the acidic pH found at their sites of action, 721 
particularly the skin [131,290]. Consistent with these observations, the major structure / function 722 
relationships that promote the pH dependent activity of the antimicrobial molecules reviewed here 723 
are those involving amino acid residues that become protonated under acid conditions, including 724 
histidine, aspartic acid and glutamic acid residues. Under these pH conditions, the protonation of 725 
these residues will have the overall effect of increasing the cationicity or decreasing the anionicity of 726 
the parent molecule thereby, enhancing its ability to target and interact with negatively charged 727 
components of microbial membranes. Typical examples include hebraein [224] and clavanins [74-79], 728 
and in the case of Ci-PAP-A22 and Ci-MAM-A24, it appears that the histidine mediated variation in 729 
the cationicity of these peptides facilitates optimal interaction with target microbial membranes on a 730 
species to specific basis [65,66]. However, given the high incidence of histidine residues in the 731 
antimicrobial molecules reviewed here, it is worthy of note that the possession of these residues is 732 
not necessarily sufficient for a pH dependent mode of antimicrobial action. This point is well 733 
illustrated by Pc-pis, from the yellow croaker, Pseudosciaena crocea, which includes a number of 734 
histidine residues in its primary structure and displays pH independent antimicrobial activity. 735 
However, the addition of a histidine residue to its sequence generated a peptide with antimicrobial 736 
activity optimal at low pH and a wider spectrum of antimicrobial activity [291].  737 
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A second major structure / function relationship for histidine, aspartic acid and glutamic acid 738 
residues in the antimicrobial action of pH dependent AMPs and proteins reviewed here is to facilitate 739 
the binding of metal ions. For example, the binding of Ca2+ by MSP at low pH potentiates the activity 740 
of the peptide by alleviating inhibitory mechanisms that are mediated by the ion [41] and metal ion 741 
binding by histidine residues appears able to promote microbial death through depletion of these 742 
ions for a number of antimicrobial molecules, such as histatins [141,143,155]. In contrast, the binding 743 
of metal ions appears to potentiates the activity of some antimicrobial molecules reviewed here by 744 
promoting their capacity to form peptide-membrane or peptide-peptide salt bridges and thereby 745 
disrupt microbial membranes, as proposed for kappacins [197] and DCD-1(L) respectively [54]. 746 
However, the most common structure / function relationships for histidine, aspartic acid and 747 
glutamic acid residues in the antimicrobial action of the molecules reviewed here is to directly 748 
promote the disruption of target microbial membranes. For example, in the case of several 749 
antimicrobial proteins, the protonation of histidine residues appears to be a molecular switch that 750 
initiates oligomerisation and the formation of discrete channels or pores by the protein, as in the case 751 
of acanthaporin [88]. In some cases though, histidine, aspartic acid and glutamic acid residues appear 752 
to play multiple roles in promoting the activity of their parent antimicrobial molecules. For example, 753 
the N-terminal regions of gad-1 and gad-2 include a number of sequential histidine pairs that appear 754 
to be important to their ability for lipid targeting and interaction, channel formation and thereby the 755 
disruption of microbial membranes at low pH [33,34,94,99,100].   756 
A further major structure / function relationship involved in the mechanisms of the antimicrobial 757 
molecules reviewed here is pH related conformational change in ΅-helical architecture, which is by 758 
far the most common secondary structural element identified in these AMPs and antimicrobial 759 
proteins. Indeed, it well established that histidine, glutamic acid and aspartic acid residues have a 760 
strong potential for ΅-helical formation that is enhanced by low pH [98,292]. The pore forming 761 
antimicrobial proteins reviewed here are strongly ΅-helical (Figure 2) and it is known that changes to 762 
the levels of ΅-helical architecture possessed by these proteins are enhanced by low pH, which 763 
promotes their pore forming mechanisms and are key to their ability to kill microbes [39,86,88,93]. A 764 
full description of these conformational changes is beyond the scope of this review but as an example, 765 
the protonation of C-terminal histidine residues by low pH promotes conformational changes that 766 
lead to the construction of hexameric membrane pores via the formation of active dimers from 767 
inactive monomers in the case of amoebapores [83,85,231] caenopores [89-93] and psoriasin [38-40]. 768 
The pore forming mechanism of acanthaporin, shows similarities to those of these latter proteins and 769 
also results in the formation of hexameric membrane pores. However, in the case of acanthaporin, 770 
the low pH mediated protonation of C-terminal histidine residues promotes conformational changes 771 
that induce pore formation via the formation of active dimers from inactive monomers [88]. Strictly, 772 
based on is size, lactoferrin is an antimicrobial protein, but it is often classified with AMPs due to its 773 
ubiquity in body fluids and its ability to kill bacteria using membrane interactive mechanisms with 774 
similarities to those of these latter peptides [29]. However, lactoferrin was first characterized as an 775 
iron binding protein and sequestration of the metal was initially believed to form the basis of its 776 
antibacterial mechanism although the protein is now known to use multiple iron-independent 777 
mechanisms in its activity against microbes [162,293]. 778 
In relation to the AMPs reviewed here low pH generally increased their levels of ΅-helical 779 
secondary structure and thereby enhanced their capacity for membrane interaction and antimicrobial 780 
activity. However, alkaline conditions promoted maximal levels of ΅-helical structure in E2EM-lin, 781 
which appeared to promote monomer association, pore formation and membrane interaction at the 782 
peptideȂs high pH optimum (Table 4, Figure 1). In contrast, to these latter AMPs, gad-1 and gad-2 783 
were found to possess minimal levels of ΅-helical structure under the low pH conditions that were 784 
optimal for their membrane interactions and antimicrobial activity [33]. These observations would 785 
seem to clearly indicate that pH dependent structural plasticity is an important factor in the 786 
antimicrobial mechanisms of many of the AMPs reviewed here. This form of structural plasticity 787 
would appear to be key to facilitating the appropriate balance between the amphiphilicity and 788 
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hydrophobicity of these peptides that is required for their membranolytic action at optimal pH, as 789 
proposed for gad-1 and gad-2 [33]. Reinforcing this proposal, other amino acid residues have been 790 
reported to contribute to the structural plasticity of the ΅-helical AMPs reviewed here including 791 
glycine, phenylalanine and post-translationally modified residues. These residues appear to enhance 792 
the conformational flexibility and structural hydrophobicity of tunicate clavaspirin, clavanins and 793 
styelins for bilayer partitioning and antimicrobial action at their low pH optimum [72,73].   794 
The antimicrobial mechanisms of several AMPs reviewed here appear to be described by models 795 
of membrane interaction, including variants of the carpet, toroidal pore and barrel-stave pore 796 
mechanisms. These models of membrane interaction differ fundamentally to the pore forming 797 
mechanisms of the antimicrobial proteins described above and were primarily proposed to describe 798 
the membrane spanning abilities of AMPs, which are generally up to 50 residues in length [23]. A 799 
number of novel antimicrobial mechanisms for AMPs have also been revealed by this review, such 800 
as that described for human lactoferrin, which at sub lethal levels appears to kill microbes via the pH 801 
dependent dissipation of microbial PMF [51]. The microbial PMF is an emerging potential target for 802 
the development of novel AMPs and antimicrobial proteins based on the fact that the temporary 803 
membrane perturbations caused by their action can have a large negative impact on bacterial 804 
metabolism, affecting a diverse array of cellular processes that depend upon the PMF [294-299]. This 805 
review has also described novel examples of pH dependent AMPs produced by the reduction of 806 
cysteine stabilized parent AMPs including myt Cc [63,202] and E2EM-lin (Table 4, Figure 1, [114,115])  807 
and it has been recently shown that the free cysteines of reduced AMPs play an important role in 808 
their antimicrobial activity [116,117]. Moreover, it was speculated above that the antimicrobial 809 
activity of E2EM-lin may involve pore formation via self-association and interestingly, recent work 810 
has suggested that free cysteine residues may play a role in the antimicrobial activity of AMPs by 811 
facilitating the oligomerisation of these peptides [300]. Taken together, these reports show that AMPs 812 
with pH dependent antimicrobial activity contribute to the accumulating evidence that the 813 
endogenous reduction of cysteine-stabilized AMPs is a strategy used by hosts to generate novel 814 
peptides that enhance the efficacy of their antimicrobial capacity [116,117].  815 
A number of the AMPs and antimicrobial proteins reviewed here, along with their derivatives, 816 
have been developed for multiple medical purposes, which in some cases has led to patents and the 817 
successful completion of clinical trials, and include kappacins, LL-37, histatins, lactoferrin and 818 
clavanins. Major examples of the application of these AMPs and proteins include the treatment of 819 
multiple cancers along with viral infections, such as the common cold; bacterial infections, including 820 
those associated with implants, otitis media, neutropenia and CF; and fungal infections, particularly, 821 
those detrimental to oral health. These AMPs and proteins also show the potential to induce wound 822 
healing, such as for diabetic patients and burn victims, and interestingly, a recent report has indicated 823 
that wound healing is accelerated by an acidic environment, which promotes a range of beneficial 824 
effects including increases in antimicrobial activity and the enhancement of epithelization and 825 
angiogenesis [301]. In general, the therapeutic administration of the AMPs and proteins involve 826 
topical application, such as the use of mouth washes, cream formulations and hydrogel delivery 827 
systems. These observations raise an interesting point in that most clinical trials to date involve the 828 
treatment of skin infections or the prevention of surface colonization by microbes, particularly sessile 829 
forms of these organisms, which potentially, can indicate a wide variation in local pH conditions. A 830 
comprehensive understanding of the effect of pH on the antimicrobial activity of the molecule under 831 
development would therefore seem necessary. Nonetheless, this is not generally the case and data 832 
cited in the literature in relation to the antimicrobial activity of AMPs and proteins is usually that 833 
determined under neutral pH conditions [133]. These observations clearly suggest that when 834 
characterizing the antimicrobial action of AMPs, the optimal pH for their action against individual 835 
microbes should be determined. This point is well illustrated by recent studies, which investigated 836 
the antimicrobial action of a range of synthetic AMPs and found that high pH inhibited the action of 837 
these peptides against fungi and  Gram-negative bacteria but the opposite pH trend was observed 838 
for Gram-positive bacteria [302]. 839 
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5. Conclusions 840 
This review has shown that AMPs and proteins with pH dependent antimicrobial activity are 841 
increasingly being reported and that progress has been made in understanding the structure / 842 
function relationships and mechanisms underpinning this activity. This review has also shown that 843 
there has been considerable therapeutic development of pH dependent antimicrobial molecules to 844 
treat a variety of infections and other conditions. However, one of the biggest therapeutic and 845 
biotechnical developments of these antimicrobial molecules has been to provide guidance to the 846 
design of novel compounds with pH dependent activity against: bacteria [303,304], fungi [50,305,306] 847 
and cancer cells [307,308] as well as applications involving drug [309,310] and gene delivery [311,312]. 848 
As a specific example, most AMPs designed to target the low pH of tumor tissue are cationic and 849 
cytotoxicity to healthy tissue at physiological pH has often been an issue for these peptides 850 
[98,279,280]. To address this issue, a peptide based on magainin 2 from X. laevis was designed to 851 
possess a negative charge at neutral pH that switched to a strong positive charge at low pH for cancer 852 
targeting. Designated, HE, this novel peptide, killed human renal adenocarcinoma at low pH via 853 
membranolytic mechanisms and was nontoxic towards healthy human cells across low and neutral 854 
pH conditions, making it a promising lead compound for cancer therapy [313]. As a further example, 855 
chronic infections due to P. aeruginosa are responsible for the majority of the morbidity and mortality 856 
in patients with CF and the persistence of these infections is largely due to the organism adopting a 857 
biofilm mode of growth, thereby acquiring high resistance to most antibiotics [314,315]. In response, 858 
the peptide, WLBU2, was designed and found able to prevent biofilm formation by P. aeruginosa 859 
under the low pH and high salt conditions characteristic of the CF airway without negative effects 860 
on human airway epithelial cells. WLBU2 was also found able to synergize the action of commonly 861 
used antibiotics, such as tobramycin and meropenem, making the peptide an attractive proposition 862 
to help address the critical need for novel therapeutics able to suppress chronic CF lung infections 863 
[316]. Using another approach, it has also been proposed that increasing the airway pH in CF 864 
individuals by activating CFTR independent HCO3− transport pathways or by inhibiting proton 865 
pumps could help prevent or reduce bacterial and viral infections associated with the disease 866 
[165,180,181]. Nonetheless, this review has shown that many pH dependent AMPs and antimicrobial 867 
proteins have yet to be fully characterized and it is proposed that these antimicrobial molecules merit 868 
far more research attention than they currently receive.  Indeed, pH dependent AMPs and 869 
antimicrobial proteins appear to represent an untapped source of novel biologically active agents that 870 
is awaiting full exploitation and could aid fulfillment of the urgent need for alternatives to 871 
conventional antibiotics, helping to avert a return to the pre-antibiotic era. 872 
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